Page 16 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

MCL: Event-Free Survival at 2 Years Bodes Well

Patients with mantle cell lymphoma (MCL) who survive 2 years without disease recurrence or progression live nearly as long as age- and sex-matched individuals in the general population. ....

United States , Yucai Wang , Eli Lilly , Matthew Matasar , Rutgers Cancer Institute Of New Jersey , University Of Iowa , Rwjbarnabas Health , Mayo Clinic , Lymphoma Specialized Program , Rutgers Cancer Institute , New Jersey , Mantle Cell Lymphoma , Malignant Lymphoma , Biologic Therapy , Disease Recurrence , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Hematopoietic Stem Cell Transplantation , Stem Cell Transplantation , Stem Cell Therapy , Herapy Stem Cell , Antineoplastic Drug , Nti Cancer Agents ,

Six Obstacles in Breast Cancer Detection and Treatment

At a recent conference, oncologists outlined key challenges that need to be addressed to improve breast cancer diagnosis and treatment. ....

Ann Arbor , United States , San Antonio , University Hospital , Christine Ambrosone , Angela Demichele , Nadia Harbeck , Matthew Ellis , Fabrice Andr , Regina Barzilay , Roswell Park Comprehensive Cancer Center , Massachusetts Institute Of Technology , Drug Administration , University Of North Carolina , Gustave Roussy Cancer Center , Siteman Cancer Center , University Of Michigan , Patient Advocates For Research Council , Washington University , University Of Pennsylvania Abramson Cancer Center , Washington University In St , Abramson Cancer , San Antonio Breast Cancer , Massachusetts Institute , Lori Pierce , Patty Spears ,

Combo Therapy for Advanced NSCLC Provides PFS Benefit

Combining a TKI with chemo or an antiangiogenic agent may prolong PFS in advanced NSCLC with certain mutations. The study was published as a preprint and has not yet been peer reviewed. ....

National Natural Science Foundation Of China , National Natural Science Foundation , Lung Cancer , Ung Carcinoma , Ancer Lung , Small Cell Lung Cancer , Genomic Medicine , Edicine Genomic , Peer Review , Biologic Therapy , Alignant Neoplasia , Epidermal Growth Factor Receptor , Tyrosine Kinase Inhibitor , Patient Safety , Adverse Effects , Side Effects , Tyrosine Kinase ,

CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib

The second-generation Bruton s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) . ....

United States , University Of Pennsylvania , Dana Farber Cancer Institute , Verastem Secura Bio , Bristol Myers Squibb Juno Celgene , Stefank Barta , Jenniferr Brown , Acerta Astrazeneca , Zanubrutinib Brukinsa , Genentech Roche , Loxo Lilly , American Society Of Hematology , Drug Administration , National Comprehensive Cancer Network , Chronic Lymphocytic Leukemia At Dana Farber Cancer Institute , Chronic Lymphocytic Leukemia , American Society , Secura Bio , Grifols Worldwide Operations , Tyrosine Kinase Inhibitor , Biologic Therapy , Tyrosine Kinase , Mantle Cell Lymphoma , Malignant Lymphoma , Alignant Neoplasia , Atrial Fibrillation ,

Capecitabine's Label Updated Under FDA Project Renewal Initiative

Project Renewal is updating the labels of older oncology drugs to reflect current evidence. ....

Oncology Center , Drug Administration , Project Renewal , Patient Safety , Colorectal Cancer , Antineoplastic Drug , Nti Cancer Agents , Breast Cancer , Alignant Breast Neoplasm , Metastatic Breast Carcinoma , Clinical Guidelines , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer , Malignant Pancreatic Neoplasm , Pancreatic Cancer , Ancer Pancreatic ,